Clinical Trial Update: Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of alisertib in combination with weekly paclitaxel in East Asian patients with advanced solid tumors and ovarian cancer was terminated; results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• Alisertib (alisertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-05-02